PHARM Share Price Performance
€1.43
0.50 (53.58%)
32.5% undervalued intrinsic discount
€2.11
Fair Value
Price €1.43
AnalystConsensusTarget €2.11
AnalystHighTarget €2.45
AnalystLowTarget €1.70
Fair Value€2.11
Share Pricen/a
Pharming Group N.V. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 51 Fair Values set on narratives written by author
PHARM Community Narratives
AN
Fair Value €2.11 32.5% undervalued intrinsic discount
Rare Disease Therapies And Expanded Diagnoses Will Drive Strong Long Term Upside
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value €2.45 41.8% undervalued intrinsic discount
Rare Disease Expansion Will Drive Durable Long Term Upside In This Biotech
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value €1.7 16.1% undervalued intrinsic discount
APDS Prevalence Uncertainty And Pipeline Delays Will Test Long-Term Rare Disease Thesis
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
APDS Prevalence Uncertainty And Pipeline Delays Will Test Long-Term Rare Disease Thesis
Catalysts About Pharming Group Pharming Group focuses on rare disease treatments, with commercial therapies for hereditary angioedema and APDS and a late stage program in primary mitochondrial disease. What are the underlying business or industry changes driving this perspective?Read more
0
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
€1.7
16.1% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
1.24% p.a.
Profit Margin
1.73%
Future PE
144.88x
Price in 2029
€1.99
Rare Disease Expansion Will Drive Durable Long Term Upside In This Biotech
Catalysts About Pharming Group Pharming Group is a commercial-stage biotech company focused on developing and marketing innovative therapies for rare and ultra-rare diseases. What are the underlying business or industry changes driving this perspective?Read more
70
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
€2.45
41.8% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
12.22% p.a.
Profit Margin
26.9%
Future PE
9.92x
Price in 2028
€2.87
Rare Disease Therapies And Expanded Diagnoses Will Drive Strong Long Term Upside
Catalysts About Pharming Group Pharming Group is a rare disease biotechnology company focused on developing and commercializing innovative therapies for patients with significant unmet medical needs. What are the underlying business or industry changes driving this perspective?Read more
41
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
€2.11
32.5% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
3.17% p.a.
Profit Margin
8.66%
Future PE
33.72x
Price in 2028
€2.47
Trending Discussion
Recently Updated Narratives
AN
APDS Prevalence Uncertainty And Pipeline Delays Will Test Long-Term Rare Disease Thesis
Fair Value: €1.7 16.1% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rare Disease Expansion Will Drive Durable Long Term Upside In This Biotech
Fair Value: €2.45 41.8% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rare Disease Therapies And Expanded Diagnoses Will Drive Strong Long Term Upside
Fair Value: €2.11 32.5% undervalued intrinsic discount
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Pharming Group N.V. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- 0.00056
- 89.90%
- 0.11%
- 37.2%
About PHARM
- Founded
- 1988
- Employees
- 404
- CEO
- WebsiteView website
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. It has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
